Song Daichen, Yang Xiaofan, Chen Yanfei, Hu Pingping, Zhang Yingying, Zhang Yan, Liang Ning, Xie Jian, Qiao Lili, Deng Guodong, Chen Fangjie, Zhang Jiandong
Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Department of Oncology, Shandong Lung Cancer Institute, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.
School of Clinical Medicine, Jining Medical University, Jining, China.
Front Bioeng Biotechnol. 2023 Oct 3;11:1286502. doi: 10.3389/fbioe.2023.1286502. eCollection 2023.
Cancer therapies, such as chemotherapy and radiotherapy, are often unsatisfactory due to several limitations, including drug resistance, inability to cross biological barriers, and toxic side effects on the body. These drawbacks underscore the need for alternative treatments that can overcome these challenges and provide more effective and safer options for cancer patients. In recent years, the use of live bacteria, engineered bacteria, or bacterial derivatives to deliver antitumor drugs to specific tumor sites for controlled release has emerged as a promising therapeutic tool. This approach offers several advantages over traditional cancer therapies, including targeted drug delivery and reduced toxicity to healthy tissues. Ongoing research in this field holds great potential for further developing more efficient and personalized cancer therapies, such as E. coli, Salmonella, Listeria, and bacterial derivatives like outer membrane vesicles (OMVs), which can serve as vehicles for drugs, therapeutic proteins, or antigens. In this review, we describe the advances, challenges, and future directions of research on using live bacteria or OMVs as carriers or components derived from bacteria of delivery systems for cancer therapy.
癌症治疗方法，如化疗和放疗，由于存在多种局限性，往往不尽人意，这些局限性包括耐药性、无法穿越生物屏障以及对身体的毒副作用。这些缺点凸显了对替代治疗方法的需求，这种方法能够克服这些挑战，并为癌症患者提供更有效、更安全的选择。近年来，利用活细菌、工程菌或细菌衍生物将抗肿瘤药物递送至特定肿瘤部位以实现控释，已成为一种有前景的治疗手段。与传统癌症治疗方法相比，这种方法具有多个优势，包括靶向给药以及降低对健康组织的毒性。该领域正在进行的研究对于进一步开发更高效、个性化的癌症治疗方法具有巨大潜力，例如大肠杆菌、沙门氏菌、李斯特菌以及诸如外膜囊泡（OMV）等细菌衍生物，它们可作为药物、治疗性蛋白质或抗原的载体。在本综述中，我们描述了将活细菌或OMV用作癌症治疗递送系统的载体或源自细菌的组分的研究进展、挑战及未来方向。
